Baseline lymphopenia should not be used as exclusion criteria in early clinical trials investigating immune checkpoint blockers (PD-1/PD-L1 inhibitors)

Autores: Sun, R. ; Champiat, S.; Dercle, L ; Aspeslagh, S.; Castañón Álvarez, Eduardo; Limkin, E. J.; Baldini, C.; Postel-Vinay, S. ; Hollebecque, A.; Massard, C.; Ammari, S.; Deutsch, E.; Soria, J. C. ; Marabelle, A.; Ferté, C. (Autor de correspondencia)